Exenatide extended-release: a review of its use in type 2 diabetes mellitus (Q38032321)

27 August 2017

Exenatide extended-release: a review of its use in type 2 diabetes mellitus (English)

1 reference

27 August 2017

1 reference

1

Lesley J Scott

1 reference

27 August 2017

1 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

72

1 reference

27 August 2017

1679-1707

1 reference

27 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.2165/11209750-000000000-00000

27 August 2017

0 references

cites work

Diagnosis and classification of diabetes mellitus

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Projecting the future diabetes population size and related costs for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Patient adherence to medication requirements for therapy of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Incretin mimetics as emerging treatments for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Relationships of upper gastrointestinal motor and sensory function with glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

To B or not to B: (anti)bodies of evidence on the crime scene of type 1 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Management of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Evolving treatment strategies for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209750-000000000-00000

21 January 2018

1 reference

12 December 2020

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks

1 reference

12 December 2020

Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.

1 reference

12 December 2020

Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008

1 reference

12 December 2020

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

12 December 2020

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment

1 reference

12 December 2020

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

12 December 2020

Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.

1 reference

12 December 2020

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

1 reference

12 December 2020

10.2165/11209750-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22867046

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22867046